Cargando…

Amplifications of Stemness Gene Loci—New Markers for the Determination of the Need for Neoadjuvant Chemotherapy for Patients with Breast Cancer. A Prospective Study

In this prospective study, a new strategy for the prescription of neoadjuvant chemotherapy (NAC) was prospectively tested and depended on the presence of stemness gene amplifications in the tumor before treatment, which in our early studies showed a connection with metastasis. The study included 92...

Descripción completa

Detalles Bibliográficos
Autores principales: Litviakov, Nikolai V., Ibragimova, Marina K., Tsyganov, Matvey M., Kazantseva, Polina V., Doroshenko, Artem V., Garbukov, Eugeniy Yu., Frolova, Irina G., Slonimskaya, Elena M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151881/
https://www.ncbi.nlm.nih.gov/pubmed/34064798
http://dx.doi.org/10.3390/jpm11050397
_version_ 1783698488034328576
author Litviakov, Nikolai V.
Ibragimova, Marina K.
Tsyganov, Matvey M.
Kazantseva, Polina V.
Doroshenko, Artem V.
Garbukov, Eugeniy Yu.
Frolova, Irina G.
Slonimskaya, Elena M.
author_facet Litviakov, Nikolai V.
Ibragimova, Marina K.
Tsyganov, Matvey M.
Kazantseva, Polina V.
Doroshenko, Artem V.
Garbukov, Eugeniy Yu.
Frolova, Irina G.
Slonimskaya, Elena M.
author_sort Litviakov, Nikolai V.
collection PubMed
description In this prospective study, a new strategy for the prescription of neoadjuvant chemotherapy (NAC) was prospectively tested and depended on the presence of stemness gene amplifications in the tumor before treatment, which in our early studies showed a connection with metastasis. The study included 92 patients with grade IIA–IIIB luminal B breast cancer. Patients underwent a biopsy before treatment, and with the use of a CytoScan HD Array microarray (Affymetrix, Santa Clara, CA, USA), the presence of stemness gene amplifications (3q, 5p, 6p, 7q, 8q, 13q, 9p, 9q, 10p, 10q21.1, 16p, 18chr, 19p) in the tumor was determined. In group 1 (n = 41), in the presence of two or more amplifications, patients were prescribed a personalized NAC regimen. In group 2 (n = 21), if there was no amplification of stemness genes in the tumor, then patients were not prescribed NAC, and treatment began with surgery. Group 3 (n = 30) served as a historical control. The frequency of an objective response to NAC in groups 1 and 3 was 79%. Nonmetastatic survival was found in 100% of patients in group 2, who did not undergo NAC. In patients in group 1, the frequency of metastasis was 10% (4/41). At the same time, in patients in group 3, who received NAC, the rate of metastasis was 47% (14/30). The differences between group 1 and group 3 and between group 2 and group 3 were statistically significant, both by Fisher’s criterion and a log-rank test. The appointment of NAC was most feasible in patients with clones with stemness gene amplifications in the primary tumor, while in the absence of amplifications, preoperative chemotherapy led to a sharp decrease in metastasis-free survival. This strategy of NAC prescription allowed us to achieve 93% metastatic survival in patients with breast cancer.
format Online
Article
Text
id pubmed-8151881
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81518812021-05-27 Amplifications of Stemness Gene Loci—New Markers for the Determination of the Need for Neoadjuvant Chemotherapy for Patients with Breast Cancer. A Prospective Study Litviakov, Nikolai V. Ibragimova, Marina K. Tsyganov, Matvey M. Kazantseva, Polina V. Doroshenko, Artem V. Garbukov, Eugeniy Yu. Frolova, Irina G. Slonimskaya, Elena M. J Pers Med Article In this prospective study, a new strategy for the prescription of neoadjuvant chemotherapy (NAC) was prospectively tested and depended on the presence of stemness gene amplifications in the tumor before treatment, which in our early studies showed a connection with metastasis. The study included 92 patients with grade IIA–IIIB luminal B breast cancer. Patients underwent a biopsy before treatment, and with the use of a CytoScan HD Array microarray (Affymetrix, Santa Clara, CA, USA), the presence of stemness gene amplifications (3q, 5p, 6p, 7q, 8q, 13q, 9p, 9q, 10p, 10q21.1, 16p, 18chr, 19p) in the tumor was determined. In group 1 (n = 41), in the presence of two or more amplifications, patients were prescribed a personalized NAC regimen. In group 2 (n = 21), if there was no amplification of stemness genes in the tumor, then patients were not prescribed NAC, and treatment began with surgery. Group 3 (n = 30) served as a historical control. The frequency of an objective response to NAC in groups 1 and 3 was 79%. Nonmetastatic survival was found in 100% of patients in group 2, who did not undergo NAC. In patients in group 1, the frequency of metastasis was 10% (4/41). At the same time, in patients in group 3, who received NAC, the rate of metastasis was 47% (14/30). The differences between group 1 and group 3 and between group 2 and group 3 were statistically significant, both by Fisher’s criterion and a log-rank test. The appointment of NAC was most feasible in patients with clones with stemness gene amplifications in the primary tumor, while in the absence of amplifications, preoperative chemotherapy led to a sharp decrease in metastasis-free survival. This strategy of NAC prescription allowed us to achieve 93% metastatic survival in patients with breast cancer. MDPI 2021-05-11 /pmc/articles/PMC8151881/ /pubmed/34064798 http://dx.doi.org/10.3390/jpm11050397 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Litviakov, Nikolai V.
Ibragimova, Marina K.
Tsyganov, Matvey M.
Kazantseva, Polina V.
Doroshenko, Artem V.
Garbukov, Eugeniy Yu.
Frolova, Irina G.
Slonimskaya, Elena M.
Amplifications of Stemness Gene Loci—New Markers for the Determination of the Need for Neoadjuvant Chemotherapy for Patients with Breast Cancer. A Prospective Study
title Amplifications of Stemness Gene Loci—New Markers for the Determination of the Need for Neoadjuvant Chemotherapy for Patients with Breast Cancer. A Prospective Study
title_full Amplifications of Stemness Gene Loci—New Markers for the Determination of the Need for Neoadjuvant Chemotherapy for Patients with Breast Cancer. A Prospective Study
title_fullStr Amplifications of Stemness Gene Loci—New Markers for the Determination of the Need for Neoadjuvant Chemotherapy for Patients with Breast Cancer. A Prospective Study
title_full_unstemmed Amplifications of Stemness Gene Loci—New Markers for the Determination of the Need for Neoadjuvant Chemotherapy for Patients with Breast Cancer. A Prospective Study
title_short Amplifications of Stemness Gene Loci—New Markers for the Determination of the Need for Neoadjuvant Chemotherapy for Patients with Breast Cancer. A Prospective Study
title_sort amplifications of stemness gene loci—new markers for the determination of the need for neoadjuvant chemotherapy for patients with breast cancer. a prospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151881/
https://www.ncbi.nlm.nih.gov/pubmed/34064798
http://dx.doi.org/10.3390/jpm11050397
work_keys_str_mv AT litviakovnikolaiv amplificationsofstemnessgenelocinewmarkersforthedeterminationoftheneedforneoadjuvantchemotherapyforpatientswithbreastcanceraprospectivestudy
AT ibragimovamarinak amplificationsofstemnessgenelocinewmarkersforthedeterminationoftheneedforneoadjuvantchemotherapyforpatientswithbreastcanceraprospectivestudy
AT tsyganovmatveym amplificationsofstemnessgenelocinewmarkersforthedeterminationoftheneedforneoadjuvantchemotherapyforpatientswithbreastcanceraprospectivestudy
AT kazantsevapolinav amplificationsofstemnessgenelocinewmarkersforthedeterminationoftheneedforneoadjuvantchemotherapyforpatientswithbreastcanceraprospectivestudy
AT doroshenkoartemv amplificationsofstemnessgenelocinewmarkersforthedeterminationoftheneedforneoadjuvantchemotherapyforpatientswithbreastcanceraprospectivestudy
AT garbukoveugeniyyu amplificationsofstemnessgenelocinewmarkersforthedeterminationoftheneedforneoadjuvantchemotherapyforpatientswithbreastcanceraprospectivestudy
AT frolovairinag amplificationsofstemnessgenelocinewmarkersforthedeterminationoftheneedforneoadjuvantchemotherapyforpatientswithbreastcanceraprospectivestudy
AT slonimskayaelenam amplificationsofstemnessgenelocinewmarkersforthedeterminationoftheneedforneoadjuvantchemotherapyforpatientswithbreastcanceraprospectivestudy